Advantages and Disadvantages of Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
Archives of Men's Health,
卷 8 编号 1 (2024),
31 七月 2024
,
第 e14 页
https://doi.org/10.22037/amh.v8i1.48639
摘要
Neoadjuvant chemotherapy (NAC) has been a standard treatment in the management of muscle-invasive bladder cancer (MIBC), especially for cisplatin-eligible patients. However, its widespread adoption is hampered by unresolved controversies. Various systematic reviews and meta-analyses support the role of NAC in improving survival. While in a meta-analysis published by Li G and colleagues in 2017, no difference in Overall Survival (OS) was observed between the group receiving NAC and the group that did not receive NAC (1). In addition to its advantages, it is necessary to examine its possible disadvantages and challenges.
- Overall survival
- Radical cystectomy
- Bladder cancer
##submission.howToCite##
参考
Li G, Niu HM, Wu HT, Lei BY, Wang XH, Guo XB, Feng SL. Effect of cisplatin-based neoadjuvant chemotherapy on survival in patients with bladder cancer: a meta-analysis. Clinical and Investigative Medicine. 2017 Apr 26;40(2):E81-94.
Advanced Bladder Cancer Meta‐analysis Collaboration. Neo‐adjuvant chemotherapy for invasive bladder cancer. The Cochrane database of systematic reviews. 2004 Jan 26;2004(1):CD005246.
Yin M, Joshi M, Meijer RP, Glantz M, Holder S, Harvey HA, Kaag M, Fransen van de Putte EE, Horenblas S, Drabick JJ. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. The oncologist. 2016 Jun 1;21(6):708-15.
Hamid AR, Ridwan FR, Parikesit D, Widia F, Mochtar CA, Umbas R. Meta-analysis of neoadjuvant chemotherapy compared to radical cystectomy alone in improving overall survival of muscle-invasive bladder cancer patients. BMC urology. 2020 Oct 14;20(1):158.
Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, Mottet N, Joly F, Allory Y, Harter V, Culine S. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. European Urology. 2021 Feb 1;79(2):214-21.
Cowan NG, Chen Y, Downs TM, Bochner BH, Apolo AB, Porter MP, La Rochelle JC, Amling CL, Koppie TM. Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions. Advances in urology. 2014;2014(1):746298.
- 摘要 ##plugins.themes.ojsPlusA.frontend.article.viewed##: 121 ##plugins.themes.ojsPlusA.frontend.article.times##
- pdf (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 153 ##plugins.themes.ojsPlusA.frontend.article.times##